<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231207170810&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231207170810&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 07 Dec 2023 22:08:10 +0000</lastbuilddate>
<pubDate>Thu, 07 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Quality standards for artificial intelligence-based studies and clinical trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38059791/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 7;44(46):4815-4818. doi: 10.1093/eurheartj/ehad784.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38059791/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38059791</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad784>10.1093/eurheartj/ehad784</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38059791</guid>
<pubDate>Thu, 07 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-12-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Quality standards for artificial intelligence-based studies and clinical trials</dc:title>
<dc:identifier>pmid:38059791</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad784</dc:identifier>
</item>
<item>
<title>Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38059368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Dapagliflozin improved the KCCQ-TSS in patients with HF with reduced ejection fraction but did not improve KCCQ-PLS or 6MWD. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction. In a post hoc analysis including all patients across the full spectrum of ejection fraction, there was a beneficial effect of dapagliflozin on KCCQ-TSS and KCCQ-PLS but not 6MWD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 7. doi: 10.1161/CIRCULATIONAHA.123.065061. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. It is important to determine whether therapies for HF improve symptoms and functional capacity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The DETERMINE (Dapagliflozin Effect on Exercise Capacity Using a 6-Minute Walk Test in Patients With Heart Failure) double-blind, placebo-controlled, multicenter trials assessed the efficacy of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the Total Symptom Score (TSS) and Physical Limitation Scale (PLS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6-minute walk distance (6MWD) in 313 patients with HF with reduced ejection fraction (DETERMINE-Reduced) and in 504 patients with HF with preserved ejection fraction (DETERMINE-Preserved) with New York Heart Association class II or III symptoms and elevated natriuretic peptide levels. The primary outcomes were changes in the KCCQ-TSS, KCCQ-PLS, and 6MWD after 16 weeks of treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the 313 randomized patients with HF with reduced ejection fraction, the median placebo-corrected difference in KCCQ-TSS from baseline at 16 weeks was 4.23 (95% CI, 0.96, 8.22; <i>P</i>=0.022) in favor of dapagliflozin. The median placebo-corrected difference in KCCQ-PLS was 4.2 (95% CI, 0.00, 8.3; <i>P</i>=0.058). The median placebo-corrected difference in 6MWD from baseline at 16 weeks was 3.2 meters (95% CI, -6.5, 13.0; <i>P</i>=0.69). In the 504 patients with HF with preserved ejection fraction, the median placebo-corrected 16-week difference in KCCQ-TSS and KCCQ-PLS was 3.2 (95% CI, 0.4, 6.0; <i>P</i>=0.079) and 3.1 (-0.1, 5.4; <i>P</i>=0.23), respectively. The median 16-week difference in 6MWD was 1.6 meters (95% CI, -5.9, 9.0; <i>P</i>=0.67). In an exploratory post hoc analysis of both trials combined (DETERMINE-Pooled), the median placebo-corrected difference from baseline at 16 weeks was 3.7 (1.5, 5.9; <i>P</i>=0.005) for KCCQ-TSS, 4.0 (0.3, 4.9; <i>P</i>=0.036) for KCCQ-PLS, and 2.5 meters (-3.5, 8.4; <i>P</i>=0.50) for 6MWD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dapagliflozin improved the KCCQ-TSS in patients with HF with reduced ejection fraction but did not improve KCCQ-PLS or 6MWD. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction. In a post hoc analysis including all patients across the full spectrum of ejection fraction, there was a beneficial effect of dapagliflozin on KCCQ-TSS and KCCQ-PLS but not 6MWD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT03877237 and NCT03877224.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38059368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38059368</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065061>10.1161/CIRCULATIONAHA.123.065061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38059368</guid>
<pubDate>Thu, 07 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Ann Hammarstedt</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Anna Maria Langkilde</dc:creator>
<dc:creator>Barry Reicher</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Ulrica Wilderäng</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-12-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials</dc:title>
<dc:identifier>pmid:38059368</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065061</dc:identifier>
</item>
<item>
<title>Resistance Exercise Training in Individuals With and Without Cardiovascular Disease: 2023 Update: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38059362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>Resistance training not only can improve or maintain muscle mass and strength, but also has favorable physiological and clinical effects on cardiovascular disease and risk factors. This scientific statement is an update of the previous (2007) American Heart Association scientific statement regarding resistance training and cardiovascular disease. Since 2007, accumulating evidence suggests resistance training is a safe and effective approach for improving cardiovascular health in adults with and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 7. doi: 10.1161/CIR.0000000000001189. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Resistance training not only can improve or maintain muscle mass and strength, but also has favorable physiological and clinical effects on cardiovascular disease and risk factors. This scientific statement is an update of the previous (2007) American Heart Association scientific statement regarding resistance training and cardiovascular disease. Since 2007, accumulating evidence suggests resistance training is a safe and effective approach for improving cardiovascular health in adults with and without cardiovascular disease. This scientific statement summarizes the benefits of resistance training alone or in combination with aerobic training for improving traditional and nontraditional cardiovascular disease risk factors. We also address the utility of resistance training for promoting cardiovascular health in varied healthy and clinical populations. Because less than one-third of US adults report participating in the recommended 2 days per week of resistance training activities, this scientific statement provides practical strategies for the promotion and prescription of resistance training.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38059362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38059362</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001189>10.1161/CIR.0000000000001189</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38059362</guid>
<pubDate>Thu, 07 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Amanda E Paluch</dc:creator>
<dc:creator>William R Boyer</dc:creator>
<dc:creator>Barry A Franklin</dc:creator>
<dc:creator>Deepika Laddu</dc:creator>
<dc:creator>Felipe Lobelo</dc:creator>
<dc:creator>Duck-Chul Lee</dc:creator>
<dc:creator>Mary M McDermott</dc:creator>
<dc:creator>Damon L Swift</dc:creator>
<dc:creator>Allison R Webel</dc:creator>
<dc:creator>Abbi Lane</dc:creator>
<dc:creator>on behalf the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Peripheral Vascular Disease</dc:creator>
<dc:date>2023-12-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Resistance Exercise Training in Individuals With and Without Cardiovascular Disease: 2023 Update: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38059362</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001189</dc:identifier>
</item>
<item>
<title>Mosaic loss of chromosome Y and cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Dec 6. doi: 10.1038/s41569-023-00976-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057442</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00976-x>10.1038/s41569-023-00976-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057442</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Soichi Sano</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Mosaic loss of chromosome Y and cardiovascular disease</dc:title>
<dc:identifier>pmid:38057442</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00976-x</dc:identifier>
</item>
<item>
<title>Reply: Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057078/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):e237. doi: 10.1016/j.jacc.2023.10.012.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057078/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057078</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.012>10.1016/j.jacc.2023.10.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057078</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jing Fang</dc:creator>
<dc:creator>Yani Liu</dc:creator>
<dc:creator>Song Wan</dc:creator>
<dc:creator>Xiang Wei</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</dc:title>
<dc:identifier>pmid:38057078</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.012</dc:identifier>
</item>
<item>
<title>Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057077/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):e235. doi: 10.1016/j.jacc.2023.09.829.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057077/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057077</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.829>10.1016/j.jacc.2023.09.829</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057077</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Ramdas G Pai</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Potential Expanded Applications of Minimally Invasive Cardiac Myectomy</dc:title>
<dc:identifier>pmid:38057077</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.829</dc:identifier>
</item>
<item>
<title>Role of Advanced Practice Providers in the Cardiac Intensive Care Unit Team</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057076/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2338-2342. doi: 10.1016/j.jacc.2023.08.061.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057076/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057076</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.061>10.1016/j.jacc.2023.08.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057076</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Carolina D Tennyson</dc:creator>
<dc:creator>Margaret T Bowers</dc:creator>
<dc:creator>Allison W Dimsdale</dc:creator>
<dc:creator>Sharon M Dickinson</dc:creator>
<dc:creator>R Monica Sanford</dc:creator>
<dc:creator>Jordan D McKenzie-Solis</dc:creator>
<dc:creator>Hannah D Schimmer</dc:creator>
<dc:creator>Carlos L Alviar</dc:creator>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Role of Advanced Practice Providers in the Cardiac Intensive Care Unit Team</dc:title>
<dc:identifier>pmid:38057076</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.061</dc:identifier>
</item>
<item>
<title>Research Priorities in Critical Care Cardiology: JACC Expert Panel</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057075/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>Over the last several decades, the cardiac intensive care unit (CICU) has seen a substantial evolution in the patient population, comorbidities, and diagnoses. However, the generation of high-quality evidence to manage these complex and critically ill patients has been slow. Given the scarcity of clinical trials focused on critical care cardiology (CCC), CICU clinicians are often left to extrapolate from studies that either exclude or poorly represent the patient population admitted to CICUs....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2329-2337. doi: 10.1016/j.jacc.2023.09.828.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the last several decades, the cardiac intensive care unit (CICU) has seen a substantial evolution in the patient population, comorbidities, and diagnoses. However, the generation of high-quality evidence to manage these complex and critically ill patients has been slow. Given the scarcity of clinical trials focused on critical care cardiology (CCC), CICU clinicians are often left to extrapolate from studies that either exclude or poorly represent the patient population admitted to CICUs. The lack of high-quality evidence and limited guidance from society guidelines has led to significant variation in practice patterns for many of the most common CICU diagnoses. Several barriers, both common to critical care research and unique to CCC, have impeded progress. In this multinational perspective, we describe key areas of priority for CCC research, current challenges for investigation in the CICU, and essential elements of a path forward for the field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057075/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057075</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.828>10.1016/j.jacc.2023.09.828</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057075</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>P Elliott Miller</dc:creator>
<dc:creator>Kurt Huber</dc:creator>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>Konstantin A Krychtiuk</dc:creator>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:creator>Guido Tavazzi</dc:creator>
<dc:creator>Michael A Solomon</dc:creator>
<dc:creator>Steen D Kristensen</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>ACC’s Critical Care Cardiology Member Section and the ESC Association for Acute CardioVascular Care</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Research Priorities in Critical Care Cardiology: JACC Expert Panel</dc:title>
<dc:identifier>pmid:38057075</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.828</dc:identifier>
</item>
<item>
<title>Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057074/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>Disparities by sex, race, socioeconomic status, and geography exist in diagnosis, treatment, and outcomes for people with lower extremity peripheral artery disease (PAD). PAD prevalence is similar in men and women, but women have more atypical symptoms and undergo lower extremity revascularization at older ages compared to men. People who are Black have an approximately 2-fold higher prevalence of PAD, compared to people who are White and have more atypical symptoms, greater mobility loss, less...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2312-2328. doi: 10.1016/j.jacc.2023.09.830.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Disparities by sex, race, socioeconomic status, and geography exist in diagnosis, treatment, and outcomes for people with lower extremity peripheral artery disease (PAD). PAD prevalence is similar in men and women, but women have more atypical symptoms and undergo lower extremity revascularization at older ages compared to men. People who are Black have an approximately 2-fold higher prevalence of PAD, compared to people who are White and have more atypical symptoms, greater mobility loss, less optimal medical care, and higher amputation rates. Although fewer data are available for other races, people with PAD who are Hispanic have higher amputation rates than White people. Rates of amputation also vary by geography in the United States, with the highest rates of amputation in the southeastern United States. To improve PAD outcomes, intentional actions to eliminate disparities are necessary, including clinician education, patient education with culturally appropriate messaging, improved access to high-quality health care, science focused on disparity elimination, and health policy changes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057074/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057074</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.830>10.1016/j.jacc.2023.09.830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057074</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Mary M McDermott</dc:creator>
<dc:creator>Karen J Ho</dc:creator>
<dc:creator>Olamide Alabi</dc:creator>
<dc:creator>Michael H Criqui</dc:creator>
<dc:creator>Philip Goodney</dc:creator>
<dc:creator>Naomi Hamburg</dc:creator>
<dc:creator>Demetria M McNeal</dc:creator>
<dc:creator>Amy Pollak</dc:creator>
<dc:creator>Kim G Smolderen</dc:creator>
<dc:creator>Marc Bonaca</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:38057074</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.830</dc:identifier>
</item>
<item>
<title>Apixaban for Children With Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2310-2311. doi: 10.1016/j.jacc.2023.10.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057073</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.011>10.1016/j.jacc.2023.10.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057073</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Craig A Mullen</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Apixaban for Children With Heart Disease</dc:title>
<dc:identifier>pmid:38057073</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.011</dc:identifier>
</item>
<item>
<title>Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057072/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this pediatric multinational, randomized trial, bleeding and thromboembolism were infrequent on apixaban and SOC. Apixaban PK data correlated well with adult trials that demonstrated efficacy. These results support the use of apixaban as an alternative to SOC for thromboprophylaxis in pediatric heart disease. (A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist [VKA] or Low Molecular Weight Heparin [LMWH] in Pediatric Subjects With Congenital or...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2296-2309. doi: 10.1016/j.jacc.2023.10.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Children with heart disease frequently require anticoagulation for thromboprophylaxis. Current standard of care (SOC), vitamin K antagonists or low-molecular-weight heparin, has significant disadvantages.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to describe safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of apixaban, an oral, direct factor Xa inhibitor, for prevention of thromboembolism in children with congenital or acquired heart disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Phase 2, open-label trial in children (ages, 28 days to &lt;18 years) with heart disease requiring thromboprophylaxis. Randomization 2:1 apixaban or SOC for 1 year with intention-to-treat analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">PRIMARY ENDPOINT: a composite of adjudicated major or clinically relevant nonmajor bleeding. Secondary endpoints: PK, pharmacodynamics, quality of life, and exploration of efficacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 2017 to 2021, 192 participants were randomized, 129 apixaban and 63 SOC. Diagnoses included single ventricle (74%), Kawasaki disease (14%), and other heart disease (12%). One apixaban participant (0.8%) and 3 with SOC (4.8%) had major or clinically relevant nonmajor bleeding (% difference -4.0 [95% CI: -12.8 to 0.8]). Apixaban incidence rate for all bleeding events was nearly twice the rate of SOC (100.0 vs 58.2 per 100 person-years), driven by 12 participants with ≥4 minor bleeding events. No thromboembolic events or deaths occurred in either arm. Apixaban pediatric PK steady-state exposures were consistent with adult levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this pediatric multinational, randomized trial, bleeding and thromboembolism were infrequent on apixaban and SOC. Apixaban PK data correlated well with adult trials that demonstrated efficacy. These results support the use of apixaban as an alternative to SOC for thromboprophylaxis in pediatric heart disease. (A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist [VKA] or Low Molecular Weight Heparin [LMWH] in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation; NCT02981472).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057072/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057072</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.010>10.1016/j.jacc.2023.10.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057072</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>R Mark Payne</dc:creator>
<dc:creator>Kristin M Burns</dc:creator>
<dc:creator>Andrew C Glatz</dc:creator>
<dc:creator>Christoph Male</dc:creator>
<dc:creator>Andrea Donti</dc:creator>
<dc:creator>Leonardo R Brandão</dc:creator>
<dc:creator>Gunter Balling</dc:creator>
<dc:creator>Christina J VanderPluym</dc:creator>
<dc:creator>Frances Bu'Lock</dc:creator>
<dc:creator>Lazaros K Kochilas</dc:creator>
<dc:creator>Brigitte Stiller</dc:creator>
<dc:creator>James F Cnota</dc:creator>
<dc:creator>Otto Rahkonen</dc:creator>
<dc:creator>Asra Khan</dc:creator>
<dc:creator>Rachele Adorisio</dc:creator>
<dc:creator>Serban Stoica</dc:creator>
<dc:creator>Lindsay May</dc:creator>
<dc:creator>Jane C Burns</dc:creator>
<dc:creator>Jose Francisco K Saraiva</dc:creator>
<dc:creator>Kimberly E McHugh</dc:creator>
<dc:creator>John S Kim</dc:creator>
<dc:creator>Agustin Rubio</dc:creator>
<dc:creator>Nadia G Chía-Vazquez</dc:creator>
<dc:creator>Marcie R Meador</dc:creator>
<dc:creator>Joshua L Dyme</dc:creator>
<dc:creator>Alison M Reedy</dc:creator>
<dc:creator>Toni Ajavon-Hartmann</dc:creator>
<dc:creator>Praneeth Jarugula</dc:creator>
<dc:creator>Lauren E Carlson-Taneja</dc:creator>
<dc:creator>Donna Mills</dc:creator>
<dc:creator>Olivia Wheaton</dc:creator>
<dc:creator>Paul Monagle</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease</dc:title>
<dc:identifier>pmid:38057072</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.010</dc:identifier>
</item>
<item>
<title>Lipoprotein(a): More Than Just a Biomarker of Myocardial Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057071/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2292-2295. doi: 10.1016/j.jacc.2023.10.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057071</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.019>10.1016/j.jacc.2023.10.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057071</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Gilles Lambert</dc:creator>
<dc:creator>Kévin Chemello</dc:creator>
<dc:creator>Antonio Gallo</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a): More Than Just a Biomarker of Myocardial Fibrosis</dc:title>
<dc:identifier>pmid:38057071</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.019</dc:identifier>
</item>
<item>
<title>Association of Lipoprotein(a) Levels With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057070/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Elevated Lp(a) levels are linked to greater subclinical IMF, increased myocardial scar prevalence, and left atrial remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2280-2291. doi: 10.1016/j.jacc.2023.10.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lipoprotein(a) (Lp[a]) has been identified as an emerging risk factor for adverse cardiovascular (CV) outcomes, including heart failure. However, the connections among Lp(a), myocardial fibrosis (interstitial and replacement), and cardiac remodeling as pathways to CV diseases remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study investigated the relationship between Lp(a) levels and myocardial fibrosis by cardiac magnetic resonance (CMR) T1 mapping and late gadolinium enhancement, as well as cardiac remodeling by cine CMR, in the MESA (Multi-Ethnic Study of Atherosclerosis) cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study included 2,040 participants with baseline Lp(a) measurements and T1 mapping for interstitial myocardial fibrosis (IMF) evaluation in 2010. Lp(a) was analyzed as a continuous variable (per log unit) and using clinical cutoff values of 30 and 50 mg/dL. Multivariate linear and logistic regression were used to assess the associations of Lp(a) with CMR measures of extracellular volume (ECV fraction [ECV%]), native T1 time, and myocardial scar, as well as parameters of cardiac remodeling, in 2,826 participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Higher Lp(a) levels were associated with increased ECV% (per log-unit Lp[a]; β = 0.2%; P = 0.007) and native T1 time (per log-unit Lp[a]; β = 4%; P &lt; 0.001). Similar relationships were observed between elevated Lp(a) levels and a higher risk of clinically significant IMF defined by prognostic thresholds per log-unit Lp(a) of ECV% (OR: 1.20; 95% CI: 1.04-1.43) and native T1 (OR: 1.2; 95% CI: 1.1-1.4) equal to 30% and 955 ms, respectively. Clinically used Lp(a) cutoffs (30 and 50 mg/dL) were associated with greater prevalence of myocardial scar (OR: 1.85; 95% CI: 1.1-3.2 and OR: 1.9; 95% CI: 1.1-3.4, respectively). Finally, higher Lp(a) levels were associated with left atrial enlargement and dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Elevated Lp(a) levels are linked to greater subclinical IMF, increased myocardial scar prevalence, and left atrial remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057070/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057070</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.016>10.1016/j.jacc.2023.10.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057070</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Omar Chehab</dc:creator>
<dc:creator>Ashkan Abdollahi</dc:creator>
<dc:creator>Seamus P Whelton</dc:creator>
<dc:creator>Colin O Wu</dc:creator>
<dc:creator>Bharath Ambale-Venkatesh</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>David A Bluemke</dc:creator>
<dc:creator>Michael Y Tsai</dc:creator>
<dc:creator>João A C Lima</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Lipoprotein(a) Levels With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis</dc:title>
<dc:identifier>pmid:38057070</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.016</dc:identifier>
</item>
<item>
<title>Lipoprotein(a), Peripheral Artery Disease, and Abdominal Aortic Aneurysm: The Next Frontier or Another Risk Enhancer?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2277-2279. doi: 10.1016/j.jacc.2023.10.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057069</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.015>10.1016/j.jacc.2023.10.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057069</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:creator>Alexander E Sullivan</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a), Peripheral Artery Disease, and Abdominal Aortic Aneurysm: The Next Frontier or Another Risk Enhancer?</dc:title>
<dc:identifier>pmid:38057069</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.015</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057068/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: High Lp(a) levels increased risk of PAD, AAA, and MALE by 2- to 3-fold in the general population, opening opportunities for prevention given future Lp(a)-lowering therapies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2265-2276. doi: 10.1016/j.jacc.2023.10.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lp(a) (lipoprotein[a])-lowering therapy to reduce cardiovascular disease is under investigation in phase 3 clinical trials. High Lp(a) may be implicated in peripheral artery disease (PAD), abdominal aortic aneurysms (AAAs), and major adverse limb events (MALE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors investigated the association of high Lp(a) levels and corresponding LPA genotypes with risk of PAD, AAA, and MALE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors included 108,146 individuals from the Copenhagen General Population Study. During follow-up, 2,450 developed PAD, and 1,251 AAAs. Risk of MALE was assessed in individuals with PAD at baseline and replicated in the Copenhagen City Heart Study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Higher Lp(a) was associated with a stepwise increase in risk of PAD and AAA (P for trend &lt;0.001). For individuals with Lp(a) levels ≥99th (≥143 mg/dL, ≥307 nmol/L) vs &lt;50th percentile (≤9 mg/dL, ≤17 nmol/L), multivariable-adjusted HRs were 2.99 (95% CI: 2.09-4.30) for PAD and 2.22 (95% CI: 1.21-4.07) for AAA. For individuals with PAD, the corresponding incidence rate ratio for MALE was 3.04 (95% CI: 1.55-5.98). Per 50 mg/dL (105 nmol/L) genetically higher Lp(a) risk ratios were 1.39 (95% CI: 1.24-1.56) for PAD and 1.21 (95% CI: 1.01-1.44) for AAA, consistent with observational risk ratios of 1.33 (95% CI: 1.24-1.43) and 1.27 (95% CI: 1.15-1.41), respectively. In women smokers aged 70 to 79 years with Lp(a) &lt;50th and ≥99th percentile, absolute 10-year risks of PAD were 8% and 21%, and equivalent risks in men 11% and 29%, respectively. For AAA, corresponding risks were 2% and 4% in women, and 5% and 12% in men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: High Lp(a) levels increased risk of PAD, AAA, and MALE by 2- to 3-fold in the general population, opening opportunities for prevention given future Lp(a)-lowering therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057068/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057068</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.009>10.1016/j.jacc.2023.10.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057068</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Peter E Thomas</dc:creator>
<dc:creator>Signe Vedel-Krogh</dc:creator>
<dc:creator>Sune F Nielsen</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:creator>Pia R Kamstrup</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events</dc:title>
<dc:identifier>pmid:38057068</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.009</dc:identifier>
</item>
<item>
<title>Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057067/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2262-2264. doi: 10.1016/j.jacc.2023.10.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057067/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057067</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.020>10.1016/j.jacc.2023.10.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057067</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Abdul Mannan Khan Minhas</dc:creator>
<dc:creator>Carl E Orringer</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?</dc:title>
<dc:identifier>pmid:38057067</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.020</dc:identifier>
</item>
<item>
<title>Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38057066/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 12;82(24):2251-2261. doi: 10.1016/j.jacc.2023.10.007.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Exposure-adjusted incidence rates and Kaplan-Meier estimates of cumulative incidence of reported treatment-emergent adverse events (TEAE), abnormal laboratory measurements, and incidence of antidrug antibodies were analyzed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This analysis included 3,576 patients treated with inclisiran for up to 6 years and 1,968 patients treated with placebo for up to 1.5 years, with 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. Kaplan-Meier analyses showed that TEAEs that were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38057066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38057066</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.007>10.1016/j.jacc.2023.10.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38057066</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>R Scott Wright</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Frederick J Raal</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>Pierre Maheux</dc:creator>
<dc:creator>Christian Stratz</dc:creator>
<dc:creator>Xiao Zang</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials</dc:title>
<dc:identifier>pmid:38057066</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.007</dc:identifier>
</item>
<item>
<title>Choroid plexus mast cells drive tumor-associated hydrocephalus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38056463/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>Tumor-associated hydrocephalus (TAH) is a common and lethal complication of brain metastases. Although other factors beyond mechanical obstructions have been suggested, the exact mechanisms are unknown. Using single-nucleus RNA sequencing and spatial transcriptomics, we find that a distinct population of mast cells locate in the choroid plexus and dramatically increase during TAH. Genetic fate tracing and intracranial mast-cell-specific tryptase knockout showed that choroid plexus mast cells...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 28:S0092-8674(23)01182-0. doi: 10.1016/j.cell.2023.11.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tumor-associated hydrocephalus (TAH) is a common and lethal complication of brain metastases. Although other factors beyond mechanical obstructions have been suggested, the exact mechanisms are unknown. Using single-nucleus RNA sequencing and spatial transcriptomics, we find that a distinct population of mast cells locate in the choroid plexus and dramatically increase during TAH. Genetic fate tracing and intracranial mast-cell-specific tryptase knockout showed that choroid plexus mast cells (CPMCs) disrupt cilia of choroid plexus epithelia via the tryptase-PAR2-FoxJ1 pathway and consequently increase cerebrospinal fluid production. Mast cells are also found in the human choroid plexus. Levels of tryptase in cerebrospinal fluid are closely associated with clinical severity of TAH. BMS-262084, an inhibitor of tryptase, can cross the blood-brain barrier, inhibit TAH in vivo, and alleviate mast-cell-induced damage of epithelial cilia in a human pluripotent stem-cell-derived choroid plexus organoid model. Collectively, we uncover the function of CPMCs and provide an attractive therapy for TAH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38056463/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38056463</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.001>10.1016/j.cell.2023.11.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38056463</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yiye Li</dc:creator>
<dc:creator>Can Di</dc:creator>
<dc:creator>Shijian Song</dc:creator>
<dc:creator>Yubo Zhang</dc:creator>
<dc:creator>Yiwen Lu</dc:creator>
<dc:creator>Jianyou Liao</dc:creator>
<dc:creator>Bingxi Lei</dc:creator>
<dc:creator>Jian Zhong</dc:creator>
<dc:creator>Kaihua Guo</dc:creator>
<dc:creator>Nu Zhang</dc:creator>
<dc:creator>Shicheng Su</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Choroid plexus mast cells drive tumor-associated hydrocephalus</dc:title>
<dc:identifier>pmid:38056463</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.001</dc:identifier>
</item>
<item>
<title>An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38056462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>Acyl-coenzyme A (acyl-CoA) species are cofactors for numerous enzymes that acylate thousands of proteins. Here, we describe an enzyme that uses S-nitroso-CoA (SNO-CoA) as its cofactor to S-nitrosylate multiple proteins (SNO-CoA-assisted nitrosylase, SCAN). Separate domains in SCAN mediate SNO-CoA and substrate binding, allowing SCAN to selectively catalyze SNO transfer from SNO-CoA to SCAN to multiple protein targets, including the insulin receptor (INSR) and insulin receptor substrate 1 (IRS1)....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 30:S0092-8674(23)01226-6. doi: 10.1016/j.cell.2023.11.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Acyl-coenzyme A (acyl-CoA) species are cofactors for numerous enzymes that acylate thousands of proteins. Here, we describe an enzyme that uses S-nitroso-CoA (SNO-CoA) as its cofactor to S-nitrosylate multiple proteins (SNO-CoA-assisted nitrosylase, SCAN). Separate domains in SCAN mediate SNO-CoA and substrate binding, allowing SCAN to selectively catalyze SNO transfer from SNO-CoA to SCAN to multiple protein targets, including the insulin receptor (INSR) and insulin receptor substrate 1 (IRS1). Insulin-stimulated S-nitrosylation of INSR/IRS1 by SCAN reduces insulin signaling physiologically, whereas increased SCAN activity in obesity causes INSR/IRS1 hypernitrosylation and insulin resistance. SCAN-deficient mice are thus protected from diabetes. In human skeletal muscle and adipose tissue, SCAN expression increases with body mass index and correlates with INSR S-nitrosylation. S-nitrosylation by SCAN/SNO-CoA thus defines a new enzyme class, a unique mode of receptor tyrosine kinase regulation, and a revised paradigm for NO function in physiology and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38056462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38056462</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.009>10.1016/j.cell.2023.11.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38056462</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Hua-Lin Zhou</dc:creator>
<dc:creator>Zachary W Grimmett</dc:creator>
<dc:creator>Nicholas M Venetos</dc:creator>
<dc:creator>Colin T Stomberski</dc:creator>
<dc:creator>Zhaoxia Qian</dc:creator>
<dc:creator>Precious J McLaughlin</dc:creator>
<dc:creator>Puneet K Bansal</dc:creator>
<dc:creator>Rongli Zhang</dc:creator>
<dc:creator>James D Reynolds</dc:creator>
<dc:creator>Richard T Premont</dc:creator>
<dc:creator>Jonathan S Stamler</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling</dc:title>
<dc:identifier>pmid:38056462</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.009</dc:identifier>
</item>
<item>
<title>Female Patient Presenting With Increasing Pedal Edema</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38055286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 6. doi: 10.1001/jamacardio.2023.4495. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38055286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38055286</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4495>10.1001/jamacardio.2023.4495</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38055286</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Vinesh Appadurai</dc:creator>
<dc:creator>Neela Thangada</dc:creator>
<dc:creator>Akhil Narang</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Female Patient Presenting With Increasing Pedal Edema</dc:title>
<dc:identifier>pmid:38055286</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4495</dc:identifier>
</item>
<item>
<title>Sudden ST-Segment Changes in a Critically Ill Patient</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38055285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231207170810&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 6. doi: 10.1001/jamacardio.2023.4490. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38055285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231207170810&v=2.17.9.post6+86293ac">38055285</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4490>10.1001/jamacardio.2023.4490</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38055285</guid>
<pubDate>Wed, 06 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jessica M Hong</dc:creator>
<dc:creator>Ching Zhu</dc:creator>
<dc:creator>Marcella C Press</dc:creator>
<dc:date>2023-12-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sudden ST-Segment Changes in a Critically Ill Patient</dc:title>
<dc:identifier>pmid:38055285</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4490</dc:identifier>
</item>





























</channel>
</rss>